Ixaka (formerly Rexgenero) Launches as an Integrated Cell and Gene Therapy Company
The Pharma Data
JANUARY 17, 2021
Joe Dupere, CEO of Ixaka, commented: “Ixaka’s broad offering of integrated cell and gene therapy capabilities, encompassing cell-based products and an innovative in vivo gene delivery platform, provides a strong foundation for our ambitions to become a leader in cell and gene therapies. A total of $15.4
Let's personalize your content